{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:09:49Z","timestamp":1777936189721,"version":"3.51.4"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.2169\/internalmedicine.6097-25","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:08:00Z","timestamp":1759961280000},"page":"1285-1289","source":"Crossref","is-referenced-by-count":1,"title":["Persistent Unilateral Pleural Effusion with Chimeric Antigen Receptor T-cell Infiltration in Primary Mediastinal Large B-cell Lymphoma"],"prefix":"10.2169","volume":"65","author":[{"given":"Hiroyoshi","family":"Hayashi","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Shindo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Koya","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Shiozawa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Masuda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honomi","family":"Kawase","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Miyata","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Center for Transfusion Medicine and Cell Therapy, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Koda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"},{"name":"Division of Molecular Oncology, National Cancer Center Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380: 45-56, 2019.","DOI":"10.1056\/NEJMoa1804980"},{"key":"2","unstructured":"2. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20: 31-42, 2019."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396: 839-852, 2020.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mirza AS, Kumar A, Hashmi H, et al. Incidence and management of effusions before and after CD19-directed chimeric antigen receptor (CAR) T cell therapy in large B cell lymphoma. Transplant Cell Ther 27: 242.e1-242.e6, 2021.","DOI":"10.1016\/j.jtct.2020.12.025"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gutierrez C, Neilan TG, Grover NS. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy. Blood 141: 2452-2459, 2023.","DOI":"10.1182\/blood.2022017579"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chen HH, Kuo CY, Ho CL, Chen YC. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: a case report. Medicine 102: E35432, 2023.","DOI":"10.1097\/MD.0000000000035432"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368: 1408-1416, 2013.","DOI":"10.1056\/NEJMoa1214561"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mart\u00edn A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study. Haematologica 93: 1829-1836, 2008.","DOI":"10.3324\/haematol.13440"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38: 155-165, 2020.","DOI":"10.1200\/JCO.19.00172"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Buege MJ, Dao PH, Drill E, et al. IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: real-world experience in the modern era. Clin Lymphoma Myeloma Leuk 21: 873-878, 2021.","DOI":"10.1016\/j.clml.2021.07.024"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Oluwole OO, Bouabdallah K, Mu\u00f1oz J, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 194: 690-700, 2021.","DOI":"10.1111\/bjh.17527"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25: 625-638, 2019.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Light RW. Clinical practice. Pleural effusion. N Engl J Med 346: 1971-1977, 2002.","DOI":"10.1056\/NEJMcp010731"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Holland EM, Yates B, Ling A, et al. Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. Blood Adv 6: 2167-2182, 2022.","DOI":"10.1182\/bloodadvances.2021006035"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Strati P, Ahmed S, Furqan F, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137: 3272-3276, 2021.","DOI":"10.1182\/blood.2020008865"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/9\/65_6097-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:22:08Z","timestamp":1777692128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/9\/65_6097-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6097-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"6097-25"}}